文献速递痛风与晶体性关节病

在基层医疗中应用新型疾病管理项目改善痛风结局:一项试点研究

Improved Gout Outcomes in Primary Care Using a Novel Disease Management Program: A Pilot Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-01-01

该试点研究在两家大型基层医疗站点中比较了多组分痛风管理改进干预与无干预对照,干预6个月后干预站点三项痛风质量指标均显著改善,且监测率和达标率均高于对照站点,但治疗率较对照无显著改善。

要点

  • 干预6个月后干预站点治疗率从54.4%升至61.1%,监测率从56.1%升至79.2%,达标率从26.85%升至43.3%。
  • 6个月时干预站点监测率79.2% vs 对照53.4%,达标率43.3% vs 对照28.3%,均高于对照。
  • 治疗率与对照站点相比无显著改善。

核心结论

  • 一项多组分痛风管理试点项目可显著改善基层医疗痛风管理绩效。

研究设计与样本

  • 选择两家大型基层医疗站点,一家接受干预,另一家为无干预对照。
  • 干预包括动员干预站点工作人员、调查提供者绩效改进偏好、现场实时与持续在线教育,并构建电子健康记录提醒。
  • 两站点每月评估3项质量指标:接受降尿酸治疗痛风患者百分比、接受治疗患者中监测血清尿酸的百分比、接受治疗患者中血清尿酸达目标≤6.0 mg/dl的百分比。
  • 干预站点提供者每月收到与其同侪比较的指标报告。

主要发现

  • 6个月时干预站点3项痛风绩效指标均显著改善:治疗百分比从54.4%升至61.1%(OR 1.19[95%CI 1.08-1.31];P<0.001)。
  • 监测百分比从56.1%升至79.2%(OR 1.52[95%CI 1.24-1.87];P<0.001)。
  • 达标百分比从26.85%升至43.3%(OR 1.43[95%CI 1.16-1.77];P<0.001)。
  • 干预后6个月,干预站点痛风患者监测率79.2% vs 对照站点53.4%(OR 3.54[95%CI 2.30-5.45];P<0.001),达标率43.3% vs 对照站点28.3%(OR 1.99[95%CI 1.33-2.96];P<0.001),均高于对照站点。
  • 治疗人数较对照站点无显著改善。

关键数值与推荐

  • 目标血清尿酸阈值定义为≤6.0 mg/dl。
  • 干预站点治疗百分比从54.4%升至61.1%(OR 1.19[95%CI 1.08-1.31];P<0.001)。
  • 干预站点监测百分比从56.1%升至79.2%(OR 1.52[95%CI 1.24-1.87];P<0.001)。
  • 干预站点达标百分比从26.85%升至43.3%(OR 1.43[95%CI 1.16-1.77];P<0.001)。
  • 6个月时干预站点监测率79.2% vs 对照站点53.4%(OR 3.54[95%CI 2.30-5.45];P<0.001),达标率43.3% vs 对照站点28.3%(OR 1.99[95%CI 1.33-2.96];P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To pilot a primary care gout management improvement intervention. METHODS: Two large primary care sites were selected: 1 underwent the intervention, the other, a control, underwent no intervention. The intervention consisted of engagement of intervention-site staff, surveys of provider performance improvement preferences, and onsite live and enduring online education. Electronic health record reminders were constructed. Both the intervention and control sites had 3 quality measures assessed monthly: the percentage of gout patients treated with urate-lowering therapy, the percentage of treated patients monitored with serum urate, and the percentage of treated patients at target serum urate ≤6.0 mg/dl. The intervention-site providers received monthly reports comparing their measures against their peers. RESULTS: By 6 months, the intervention site significantly improved all 3 gout performance measures. The percentage treated increased from 54.4% to 61.1% (odds ratio [OR] 1.19 [95% confidence interval (95% CI) 1.08-1.31]; P < 0.001), the percentage monitored increased from 56.1% to 79.2% (OR 1.52 [95% CI 1.24-1.87]; P < 0.001), and the percentage at goal increased from 26.85% to 43.3% (OR 1.43 [95% CI 1.16-1.77]; P < 0.001). At 6 months after intervention, gout patients at the intervention site were more likely to be monitored (79.2% versus 53.4% [OR 3.54 (95% CI 2.30-5.45)]; P < 0.001) and at goal (43.3% versus 28.3% [OR 1.99 (95% CI 1.33-2.96)]; P < 0.001) than control-site patients. Numbers treated did not significantly improve over the control site. CONCLUSION: A pilot multifaceted gout management program can significantly improve primary care gout management performance.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Bulbin D, Denio AE, Berger A, et al. Improved Gout Outcomes in Primary Care Using a Novel Disease Management Program: A Pilot Study. Arthritis Care Res (Hoboken). 2018. PMID: 29438607. doi:10.1002/acr.23544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。